Is There a Difference in the Clinical Efficacy of Diosmin and Micronized Purified Flavonoid Fraction for the Treatment of Chronic Venous Disorders? Review of Available Evidence

Michèle Cazaubon¹
Jean-Patrick Benigni²
Marcio Steinbruch³
Violaine Jabbour⁴
Christelle Gouhier-Kodas⁴

¹Private Vascular Specialist, Paris, France; ²Pedagogical Support Office, Faculty of Medicine Pitié-Salpètrière, Sorbonne University, Paris, France; ³Hospital Albert Einstein, São Paulo, Brazil; ⁴Laboratoire Innotech International, Arcueil, France

Abstract: Flavonoids are oral venoactive drugs frequently prescribed to relieve the symptoms of chronic venous disorders (CVD). Among venoactive drugs, diosmin is a naturally occurring flavonoid glycoside that can be isolated from various plant sources; it can also be obtained after conversion of hesperidin extracted from citrus rinds. Micronized purified flavonoid fraction (MPFF) is a preparation that contains mainly diosmin and a small fraction of hesperidin. We performed a state-of-the-art literature review to collect and analyze well-conducted randomized clinical studies comparing diosmin – also called non-micronized or hemisynthetic diosmin – 600 mg a day and MPFF, 1000 mg a day. Three clinical studies met the criteria and were included for this literature review. These clinical studies showed a significant decrease of CVD symptom intensity (up to approximately 50%) and global patient satisfaction after one-to-six-month treatment with diosmin or MPFF, without statistical differences between these two forms of diosmin. Both treatments were well tolerated with few mild adverse drug reactions reported. Overall, based on this literature review, there is no clinical benefit to increase the dose of diosmin beyond 600 mg per day, to use the micronized form, or to add hesperidin, since clinical efficacy on venous symptomatology is achieved with 600 mg per day of pure non-micronized diosmin. This challenges the status of diosmin – 600 mg a day – in guidelines for the management of CVD, which is currently categorized 2C (weak recommendations for use and poor quality of evidence), while the most widely used and assessed preparation MPFF is rated 1B (strong recommendation for use and moderate quality of evidence).

Keywords: chronic venous disorders, vеноactive drugs, flavonoids, randomized clinical trials, literature review

Introduction

Chronic venous disorders (CVD) can be defined as morphological and functional abnormalities of the venous system that manifest either by symptoms and/or clinical signs. CVD is generally diagnosed on the basis of medical history, clinical examination and duplex color ultrasound.¹ The main symptoms of CVD are feeling of swelling, heaviness and tightness in the legs, or pain in the lower limbs, and they increase in standing position and in summer.² The symptoms are persistent and the disease is progressive, resulting in physical, social and psychological suffering with significant negative impact on quality of life.¹,²
The CEAP (Clinical Etiology Anatomy Pathophysiology) classification of CVD is widely used to describe CVD stages, based on clinical manifestations and other characteristics of the disease. The C0–C3 stages are not associated with visible trophic disorders: C0, no signs; C1, telangiectasias or reticular veins; C2, varicose; C3, oedema. Skin changes are visible at the next stages: C4, stasis dermatitis, pigmentation, lipodermatosclerosis, atrophie blanche or corona phlebectatica; C5, healed ulceration; C6, active ulceration. The descriptor “a” or “s” can be added after the C clinical class (asymptomatic or symptomatic) as at each CEAP stage, symptoms can be present or absent. Chronic venous insufficiency refers to the most advanced stages of the disease. Venous ulcers, the ultimate stage of CVD, are present in 1–2% of the Northwestern population and are a heavy burden, both for patients and public health systems.

The precise etiology and pathogenesis of CVD remain incompletely understood, although a variety of possibly inter-related mechanisms have been proposed to be responsible for signs and symptoms, such as venous valve incompetence, structural alterations and changes in cellular components of the venous wall, inflammation of the venous wall and an increase in venous pressure. The pooling of blood in the lower extremity (prolonged standing position in normal subjects or venous incompetence in ill subjects) leads to an increase in hydrostatic pressure and in the blood flow in capillaries. The resulting venous hypertension prompts leucocyte adhesion to capillary endothelium and initializes an inflammatory reaction. The expression and activity of hypoxia-inducible factors, cytokines, reactive oxygen species or metalloproteinases increase. The extracellular matrix, which is essential for the endothelial cells’ nutrition and homeostasis, is altered. These mechanisms result in progressive dilation of the venous wall, valve incompetence and venous reflux, which may play a role in the onset of symptoms. Venous pathology could then progress through a vicious cycle of inflammation and leucocyte recruitment leading to further deteriorations.

The choice of treatment for CVD depends on the CEAP stages and different treatments are used to meet several objectives. Graduated compression stockings help fighting against venous stasis, reduce symptoms and might prevent disease progression. Oral venoactive drugs have various pharmacological actions, notably targeted at the venous wall, and are used to relieve symptoms. Creams or lotions can also be helpful to relieve symptoms. In the most advanced stages, sclerotherapy, endovenous procedures and surgery can be done to remove pathologic veins. Finally, compressive bandages improve circulation in deep veins and microvascular structures by reducing swelling and improving skin nutrition.

Oral treatments are frequently prescribed to patients suffering from symptomatic CVD. Venoactive drugs are a heterogeneous pharmacological class that comprises both synthetic and compounds extracted from plants. Among venoactive drugs, flavonoids are a class of polyphenolic compounds found in plants, and many studies have suggested that they were effective for the treatment of symptomatic CVD. Although the action of flavonoids is not fully understood, they were shown to increase the venous tone by modulating noradrenergic signaling. Moreover, in vitro and in vivo investigations suggested they could target primarily the venous wall through anti-inflammatory and antioxidant properties, which may be their key mechanisms of action. Diosmin (diosmetin 7-O-rutinoside) is a naturally occurring flavonoid glycoside that can be isolated from various plant sources or derived from hesperidin, another flavonoid which is chemically and structurally very similar. Various specialties containing diosmin are available, including micronized purified flavonoid fraction (MPFF) which contains 90% diosmin and 10% hesperidin. Micronization is a mechanical process that reduces the average diameter of solid particles to improve intestinal absorption.

Based on systematic reviews or meta-analyses of clinical studies looking at the effects of individual venoactive drugs on symptoms of CVD, MPFF was shown to be effective on improving leg symptoms, oedema, and quality of life in patients with CVD. Therefore, successive international guidelines for CVD management presented MPFF as the flavonoid preparation that achieved the highest level of recommendation, and this drug is currently considered as the reference treatment among flavonoid-based venoactive drugs. Nevertheless, the meta-analyses on which these recommendations were based did not include the clinical studies comparing diosmin, also called non-micronized or hemisynthetic diosmin, 600 mg a day and MPFF 1000 mg a day. As MPFF treatment is strongly recommended, it is worth considering other therapeutics that have been compared in terms of efficacy to this reference product. The objective of this literature review was therefore to collect and analyze randomized clinical studies with appropriate methodology comparing these two diosmin preparations, and then to assess if these studies provide sufficient robust
evidence to consider non-micronized diosmin – 600 mg a day – in international recommendations.

**Methods**

**Criteria for Considering Studies for This Review**

Only randomized clinical studies comparing the efficacy of approved doses of non-micronized diosmin or MPFF in their relevant therapeutic indication (venous symptom improvement) were selected: 600 mg per day in one intake for non-micronized diosmin and 1000 mg per day in one or two intakes for MPFF.

**Search Method for Identification of Studies**

Bibliographic databases (PubMed, Web of Science, Google Scholar) were searched from February 11th, 2021 to July 8th, 2021, using different keywords (“chronic venous disease”, “chronic venous insufficiency”, “flavonoids”, “diosmin”, “micronized purified flavonoid fraction”, “randomized clinical trial”, combined with logical AND and OR connectors). Only articles reporting clinical trials were selected; there were no limitations on language or publication date; studies from all countries were eligible for inclusion. Recent reviews, meta-analyses and personal bibliographies of experts were also consulted to complete the literature review.

Study selection was conducted in two stages: an initial screening of titles and/or abstracts to identify potentially relevant papers, followed by screening of the full-text papers identified during the initial stage.

**Results**

**Search Results**

After removing duplicate citations from the retrieved records, 285 articles were identified for further screening. A total of five records describing randomized clinical trials comparing the efficacy of non-micronized diosmin and MPFF in their relevant therapeutic indication (venous symptom improvement) were selected, and full appraisal of these publications was carried out (Figure 1).

**Selected Studies**

Among the five publications considered eligible for analysis of the full text, only three blinded, randomized trials comparing non-micronized diosmin and MPFF were selected for inclusion in the review, namely the studies of Henriet et al,17 Maruszynski et al18 and Steinbruch et al19 (Table 1). Two studies met the inclusion criteria for the literature review but were excluded after analysis of the full article. The Delecluse et al study (1991) – comparing non-micronized diosmin 300 mg twice a day and MPFF 500 mg twice a day in a single-blind scheme – concluded to a comparable efficacy of both treatments but was rejected because no statistical analysis was conducted to compare treatment groups.20 The Cospite et al study (1989) – that concluded to therapeutic advantage of MPFF – was also discarded due to important methodological concerns: MPFF was compared to non-micronized diosmin given at a lower dose than that generally recommended for approved non-micronized diosmin products for CVD treatment, no details on blinding and on galenics of the diosmin
<table>
<thead>
<tr>
<th>Study</th>
<th>Design</th>
<th>Study Groups</th>
<th>Study Objective</th>
<th>Duration</th>
<th>Inclusion Criteria</th>
<th>Primary Evaluation Criteria</th>
<th>Efficacy Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Henriet (1995)</td>
<td>Multicentric randomized double-blind study</td>
<td>Diosmin 600 (n=34) MPFF 500 (n=35)</td>
<td>To compare: Diosmin 600 mg once a day and MPFF 500 mg twice a day</td>
<td>28 days</td>
<td>Women 18 to 45 y suffering ≥6 months from functional symptoms of CVD (pain and/or heaviness in the lower limbs)</td>
<td>Weekly patient self-assessment (VAS) of pain/heaviness at D0, D7, D14, D21 and D28</td>
<td>Change from baseline of pain/heaviness assessed by patients significantly improved; p &lt; 0.0001 at each time point from D7 to D28 No difference between groups</td>
</tr>
<tr>
<td>Maruszynski (2004)</td>
<td>Multicentric randomized double-blind study</td>
<td>Diosmin 600 (n=59) MPFF 500 (n=60)</td>
<td>To compare: Diosmin 600 mg once a day and MPFF 500 mg twice a day</td>
<td>28 days</td>
<td>Women 20 to 60 y with CVD symptoms (C0-C3)</td>
<td>Weekly patient self-assessment (sum of individual scores of functional symptoms) at D0, D7, D14, D21 and D28</td>
<td>Significant decrease in symptoms in both groups No difference between treatment groups</td>
</tr>
<tr>
<td>Steinbruch (2020)</td>
<td>Multicentric non-inferiority single-blind randomized study</td>
<td>Diosmin 600 (n=57) MPFF 1000 (n=57)</td>
<td>To assess the non-inferiority of diosmin 600 mg once a day compared to MPFF 1000 mg once a day</td>
<td>6 months</td>
<td>Patients with CVD symptoms (C0-C3) between 20 and 60 mm of a 100-mm VAS (patient self-assessment)</td>
<td>Self-assessment (VAS) at M0, M2, M4 and M6 of venous symptoms in CVD patients</td>
<td>Non-inferiority was demonstrated Significant improvement of symptoms from M2, maximal at M6, in both groups (p &lt; 0.0001)</td>
</tr>
</tbody>
</table>

**Abbreviations:** CVD, chronic venous disease; D, day; M, month; MPFF, micronized purified flavonoid fraction; VAS, visual analog scale; y, years.
comparator were provided. This latter study has never been included in a systematic review or meta-analysis. In 1995, Henriet et al conducted a Phase III clinical study to compare the efficacy of non-micronized diosmin 600 mg (Diovenor® 600 mg) once a day vs MPFF 500 mg (Daflon® 500 mg) twice a day in CVD. It was a prospective, comparative, randomized, double-blind, double-dummy study performed in nine French centers in women aged 18 to 45 years old suffering from pain and/or heaviness in the two lower limbs for at least 6 months. Women showed no hemodynamic signs, no oedema or varicose veins. Patients were randomized to receive non-micronized diosmin 600 mg once a day or MPFF 500 mg twice a day (plus placebos). The primary endpoints were weekly patient self-assessment (visual analog scale; VAS) at D0, D7, D14, D21 and D28 and a clinical functional score assessed by the physician (sum of limb symptom scores: pain/heaviness, feeling of swelling, paraesthesia, each from 0 to 3). Secondary endpoints were overall effectiveness as judged by physicians’ and patients’ opinion. Sixty-nine women (mean age, 30 years) were randomized: 34 received non-micronized diosmin and 35 MPFF. Later, Maruszynski et al compared the clinical efficacy of hemisynthetic diosmin with MPFF in women with CVD symptoms in a multicenter, randomized, double-blind, double-dummy study. Women aged 20–60 years with CEAP class C0s–C3 CVD were included in three centers in Poland. The primary endpoint was the self-assessment of therapy effectiveness using a questionnaire based on a visual scale of lower limb symptom intensity. The self-assessment questionnaire consisted of six questions concerning: swelling, feeling of heaviness, leg tiredness, heat, night muscle cramps and pain. Symptom intensity, assessed on a scale from 0 to 5 points for each symptom, was recorded at D0, D7, D14, D21 and D28. Women were included in the study if they achieved a total score ≥ 6 points to the self-assessment questionnaire at the initial evaluation. The other evaluation criteria were the overall assessment according to the patient (satisfaction) and according to the physician (adequacy of the treatment to the clinical situation) at the check-up visit. Fifty-nine patients received hemisynthetic diosmin 600 mg once a day (Otrex® 600 mg) plus one placebo and 60 received MPFF 500 mg twice a day (Detralex®). The use of compression devices was not allowed during the study. Finally, a recent study conducted by Steinbruch et al assessed the clinical non-inferiority of non-micronized diosmin (Flebodia® 600 mg) compared to MPFF (Daflon® 1000 mg) over a 6-month treatment period. In this prospective, randomized, single-blind study, adult patients with symptomatic CVD of the lower limbs (CEAP classification from C0s-C3 stages; 20–60 mm on 100-mm VAS) were included. The primary endpoint was the self-assessment of the leg symptom intensity on a VAS from baseline to 6 months. Secondary endpoints were the overall satisfaction of the patients and physicians, the difficulty to swallow the pills assessed using a VAS, and the treatments’ safety. A total of 114 patients (mean age, 44.4 years; women: 90.4%) were included in six Brazilian university centers and randomized in the non-micronized diosmin group (n=57, one 600 mg tablet once a day) and the MPFF group (n=57, one 1000 mg tablet once a day). All were included in the per-protocol analysis.

Efficacy of Diosmin Compared to MPFF in the Treatment of CVD
These three blinded randomized trials comparatively assessed the efficacy of non-micronized diosmin 600 mg a day and MPFF 1000 mg a day on specific and/or global symptoms of CVD as detailed below. Since the medicines containing one of these two forms of diosmin are generally indicated for venous symptom improvement, clinical signs were not considered in this review.

Global Symptomatology
A significant reduction in the global intensity of CVD symptoms was shown in the three studies after one to six months of treatment with non-micronized diosmin 600 mg and MPFF 1000 mg, with no statistical differences between the two treatment groups. In the study conducted by Henriet et al, a global index of functional symptoms was determined by the physicians using the sum of the scores for three different symptoms – heavy legs and/or pain, sensation of lower limb oedema and paraesthesia – each symptom was scored from 0 to 3 (the highest score indicating a strong impact on the patients’ quality of life). The two treatment groups were comparable at baseline with a mean score of 4.18 ± 0.51 for the non-micronized diosmin 600 mg group and 4.91 ± 0.62 for the MPFF 1000 mg group. After one month of treatment, this index of functional symptoms was globally improved versus baseline in the two groups, with a reduction of 2.53 ± 0.63 and 3.29 ± 0.68, respectively (p < 0.0001).

Similarly, a global score of symptoms was used to determine the efficacy of the non-micronized diosmin
Patients suffering from CVD can be subject to muscle cramps. Maruszynski and his collaborators evaluated the impact of the two treatments on the occurrence of cramps in their patients, using the scale previously described (from 0 to 5 points). Results suggested that non-micronized diosmin 600 mg tends to reduce more efficiently night cramps than MPFF 1000 mg (p=0.022 on D14, p=0.096 on D21, p=0.074 on D28).

### Safety of Diosmin Compared to MPFF in the Treatment of CVD

In all the studies analysed in this review, treatment-emergent adverse events, as well as study withdrawals due to adverse events, were monitored. The most common adverse reactions reported were gastrointestinal disorders (Table 2).

In the Henriet et al study, three out of 34 patients from the non-micronized diosmin group reported...
gastralgia or headache, one of them dropped out of the trial after experiencing vomiting and diarrhoea. In the MPFF group, two out of 35 patients withdrew the trial due to gastralgia, and three others reported adverse drug reactions without discontinuing the treatment (constipation and abdominal meteorism for one patient, gastralgia or nausea for the two others). In the study conducted by Maruszynski et al, adverse reactions with non-micronized diosmin 600 mg were of two types: Calf, hands and feet oedema and body rash. In the MPFF 1000 mg group, three reaction types have been reported: Calf oedema, body rash, mouth dryness.

The percentage of patients with adverse reactions was 35.0% in the non-micronized diosmin 600 mg group and 26.7% in the MPFF 1000 mg group. Dyspepsia, nausea, diarrhoea and headache were the most frequently reported reactions in the two groups. Two patients discontinued their treatment with non-micronized diosmin because of palpitations, abdominal pain, diarrhoea and/or dyspepsia. In the MPFF group, one patient stopped his treatment due to vertigo and weight decrease.

Discussion

Venoactive drugs in CVD have been assessed in clinical studies that were generally small in size. Therefore, conclusions on the efficacy of these treatments are mainly based on meta-analyses and expert consensus statements. A Cochrane review and meta-analysis of phlebotonics for venous insufficiency, published in 2020, analyzed 56 randomized, double-blind, placebo-controlled trials involving 7690 participants. Ten trials with MPFF out of forty using flavonoids were included. The meta-analysis suggests that oral venoactive drugs considered as a whole reduce lower leg oedema (risk ratio (RR) 0.70, 95% confidence interval (CI) 0.63 to 0.78) and ankle circumference (mean difference −4.27 mm, 95% CI −5.61 to −2.93 mm) compared with placebo. Little or no effect was evidenced for ulcer healing (RR 0.94, 95% CI 0.79 to 1.13).

In the 2005 International Consensus Statement, 83 randomized studies and meta-analyses were considered, and experts evaluated the level of evidence-based medicine using three levels of recommendations, A, B and C (from large randomized clinical trials to non-randomized trials). Grade A was attributed to MPFF, calcium drosesilate and hydroxyethyl-rutosides, Grade B to Ruscus extracts and Grade C to hemisynthetic diosmin. The 2008 guidelines for the management of CVD updated the conclusions of published Cochrane reviews and 2005 International Consensus Statement (no significant changes).

Perrin and Ramelet published in 2011 a literature review to evaluate venoactive drugs using the GRADE system. In this system, recommendations are graded from 1 to 3 and level of evidence from A to C. Grade 1B was attributed to MPFF and rutosides and Grade 2C to Ruscus extracts. When the guidelines for the use of venous active drugs were updated in 2014, it was proposed to quantify the level of recommendations with the GRADE system. MPFF received 1B grade (strong recommendation for use and moderate quality of evidence) and non-micronized diosmin or synthetic diosmin received 2C grade (low recommendations and poor quality of evidence). Rutosides and Ruscus extracts received 2B grade.

In the recent 2018 Guidelines According to Scientific Evidence, published by Nicolaides and coworkers, it was proposed to update the 2014 guidelines by individualizing both symptoms and venous active drugs with ancient and

<table>
<thead>
<tr>
<th>Study</th>
<th>Non-Micronized Diosmin 600 mg</th>
<th>MPFF 1000 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Henriet (1995)</td>
<td>Vomiting and diarrhoea (n=1), gastralgia (n=1), headache (n=1) (n=3/34)</td>
<td>Gastralgia (n=3), constipation and abdominal meteorism (n=1), nausea (n=1) (n=5/35)</td>
</tr>
<tr>
<td>Maruszynski (2004)</td>
<td>Calf, hand and feet oedema, body rash (n=NI/59)</td>
<td>Calf, hand and feet oedema, body rash (n=NI/60)</td>
</tr>
<tr>
<td>Steinbruch (2020)</td>
<td>Nausea (13.3%), dyspepsia (16.7%), diarrhoea (8.3%), headache (6.7%), vertigo (6.7%) (n=21/57)</td>
<td>Nausea (20%), dyspepsia (6.7%), diarrhoea (5.0%), headache (6.7%), vertigo (3.3%) (n=16/57)</td>
</tr>
</tbody>
</table>

**Abbreviations**

n, Number of patients experiencing adverse reaction; NI, Not indicated; MPFF, micronized purified flavonoid fraction.
recent data. However, only five vеноactive specialties were considered: MPFF, *Ruscus* extract plus hesperidin methyl chalcone and ascorbic acid, hydroxyethyl-rutosides, horse chestnut seed extract and calcium dobesilate. There was no analysis of clinical trials with non-micronized or hemisynthetic diosmin.

Head-to-head comparisons are rare in clinical trials evaluating vеноactive drugs. In addition, meta-analyses preferentially select placebo-controlled studies. However, since both MPFF and non-micronized diosmin are flavonoids and MPFF is mostly composed of diosmin, these compounds are expected to share comparable pharmacological properties. Both are known to intervene in several of the pathophysiological mechanisms of CVD. Diosmin directly acts on venous tone by enhancing sympathetic-mediated venous contractility and increasing calcium sensitivity and contractility. Furthermore, MPFF and non-micronized diosmin have demonstrated a broad anti-inflammatory activity through the inhibition of leukocyte adherence to the vascular endothelium and the reduction of pro-inflammatory factor expression (e.g., TNF-α, IL-6).

This literature review identified three well-conducted multicenter randomized clinical trials with appropriate methodology comparing MPFF and non-micronized diosmin and providing consistent results. Taken all together, they indicate that clinical symptoms of CVD are improved with both treatments and that there are no significant differences between these two diosmin preparations. The recent study of Steinbruch et al. was a 6-month non-inferiority trial, and its methodology was therefore very demanding (low rate of patients lost to follow-up, low rate of protocol deviations, consistent intent-to-treat and per-protocol analyses). Despite an intermediate number of patients, the results provide a persuasive demonstration of the non-inferiority of non-micronized diosmin 600 mg compared with MPFF 1000 mg (diosmin 900 mg plus hesperidin 100 mg) after a 6-month treatment period. Furthermore, overall satisfaction of patients and physicians was good and comparable in both groups. The studies of Henriet et al. and Maruszynski et al. have also individually proven that treatment with non-micronized diosmin 600 mg or MPFF 1000 mg were equally efficient to reduce the feeling of heaviness and pain in the lower limbs after one month of treatment. Similar consistent beneficial effects of diosmin and MPFF were found across different clinical outcomes measured either objectively (oedema) or subjectively (pain, sensation of heaviness or swelling, etc.) using various assessment tools, in placebo-controlled or non-comparative randomized studies. Statistically significant reduction in pain was observed gradually over the course of treatment with MPFF and diosmin versus baseline intensity level.

The three studies considered in this review agreed on the equally good safety profile of both diosmin preparations, without serious adverse events. The higher frequency of adverse reactions in the study conducted by Steinbruch et al., compared to that observed in the two other studies presented in this review, or in other clinical trials conducted with one of the two drugs could be explained by the longer treatment duration (6 months). The adverse events reported were mainly digestive disorders which are expected adverse reactions associated with diosmin preparations.

**Conclusion**

Based on this literature review, MPFF (1000 mg once a day or 500 mg twice a day) and non-micronized diosmin (600 mg once a day) appear to have comparable clinical effects on CVD symptoms, after a short treatment duration (1 month), and also after a long-term treatment (6 months). These results are not surprising since MPFF is made of 90% diosmin. They suggest that increasing the diosmin daily dose, enhancing its bioavailability with micronization, or adding another flavonoid fraction, hesperidin, do not substantially improve the relief of symptoms. Thus, it supports that the daily dose of 600 mg diosmin is an equally valuable therapeutic option in this indication. Because clinical studies have been performed mostly with diosmin preparations in the form of MPFF, the recommendation for this flavonoid specialty is rated 1B (strong recommendation for use and moderate quality of evidence), while it is rated 2C for hemisynthetic diosmin (weak recommendation for use and poor quality of evidence). Such a difference in grading between the two formulations may not be justified and the results of this literature review suggest that the place of non-micronized diosmin might be reevaluated in the future updates of guidelines for the management of CVD. Confirmation of the findings of this review by further randomized comparative studies might help support this reassessment.

**Disclosure**

Michele Cazaubon agreed to review this article in exchange to a compensation provided by Laboratoire Innotech International. Jean-Patrick Benigni is currently under
contract with Laboratoire InnoTech International as a consultant expert providing advices on compression therapy and chronic venous disorders. Violaine Jabour and Christelle Gouhier-Kodas are employed by Laboratoire InnoTech International. Marcio Steinbruch declares that he has no conflict of interest regarding this publication. The authors report no other conflicts of interest in this work.

References


